Skip to main content
MedPathMedPath Home
Clinical Trials/ACTRN12618001260213
ACTRN12618001260213
Not yet recruiting
未知

Randomized controlled trial of a Mindfulness-Based program for symptoms of depression in people with Multiple Sclerosis

The University of Sydney0 sites125 target enrollmentJuly 25, 2018
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsMultiple SclerosisDepressionAnxietyFatiguePainNeurological - Multiple sclerosisMental Health - DepressionMental Health - Anxiety

Overview

Phase
未知
Intervention
Not specified
Conditions
Multiple Sclerosis
Sponsor
The University of Sydney
Enrollment
125
Status
Not yet recruiting
Last Updated
6 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 25, 2018
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • •Participants will be included if they:
  • •1\.Have a neurologist\-confirmed diagnosis of MS
  • •2\.18 years old or older
  • •3\.Currently live in Australia
  • •4\.Have regular access to the Internet.
  • •5\.Have sufficient English to complete questionnaires and understand program content in English.
  • •6\.If taking MS treatment, be on a consistent MS regimen for more than one month with no plans to change this.
  • •7\.If taking anti\-depressant medication, a stable dose for \> 8 weeks.

Exclusion Criteria

  • •Participants will be excluded if they:
  • •1\.Have a comorbid medical condition known to impact on cognition or physical ability
  • •2\.Have moderate\- severe cognitive deficits (\<25 on the Telephone Interview for Cognitive Status; TICS).
  • •3\.Have suicidal intent requiring emergency care
  • •4\.Have alcohol or drug abuse or dependence
  • •5\.A psychotic illness or history of bipolar disorder
  • •6\.Have received consistent psychotherapy within the last 6 months
  • •7 . Are pregnant. (Please note that if a participant becomes pregnant during the trial, this will not preclude them from continuing to participate).

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
A phase 3 study of parsaclisib plus ruxolitinib in patients with myelofibrosismyelofibrosisMedDRA version: 20.0Level: PTClassification code 10028537Term: MyelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2020-003415-98-HUIncyte Corporation212
Active, not recruiting
Phase 1
An Efficacy and Safety Study of Alirocumab in Children and Adolescents with Heterozygous Familial Hypercholesterolemia
EUCTR2017-001903-60-DESanofi-aventis recherche & développement500
Active, not recruiting
Phase 1
A Randomized, Double-Blind, Placebo-Controlled Study to Explore the Efficacy and Safety of Risperidone Long-Acting Intramuscular Injectable in the Prevention of Mood Episodes in Bipolar I Disorder, with Open-Label ExtensioBIPOLAR MANIA
EUCTR2004-003781-14-ESJohnson and Johnson Pharmaceutical Research and Development, una división de Janssen-Cilag, S.A
Active, not recruiting
Phase 1
A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Subjects with Extensive Stage Small Cell Lung Cancer (MERU)Extensive Stage Small Cell Lung Cancer (ED SCLC)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2016-003503-64-GBAbbvie Deutschland GmbH & Co. KG748
Active, not recruiting
Not Applicable
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABT 126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase InhibitorsAlzheimer's DiseaseMedDRA version: 15.1Level: LLTClassification code 10001896Term: Alzheimer's diseaseSystem Organ Class: 100000004852Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
EUCTR2011-004849-40-DEAbbVie Deutschland GmbH & Co. KG420